ライフサイエンスコーパス: BVDV

1 BVDV and related flaviviruses use the host ER as the pri

2 BVDV NS5A was found to coordinate a single zinc atom per

3 BVDV NS5B protein was active in an in vitro RNA polymera

4 BVDV rescued from the infectious cDNA clone has an in vi

5 BVDV was found to remain viable for 7 days in serum samp

6 pestiviruses, including isolates of BVDV-1, BVDV-2, border disease virus, and classical swine fever

7 represents the first expression of a type 2 BVDV E2 protein from a mammalian virus vector and raises

8 d responses was also observed with the Huh-7-BVDV replicon but was independent of NS3/4A protease act

9 We isolated a BVDV-nonpermissive MDBK cell clone that harbored a 1.2-k

10 these cysteine residues in the context of a BVDV replicon system indicated that these residues were

11 d a membrane-based assay that consisted of a BVDV RNA replicase complex isolated from virus-infected

12 Here, we report the development of a BVDV subunit vaccine by (i) the expression of a secreted

13 ell-based BVDV vaccine capable of addressing BVDV heterogeneity more effectively than current vaccine

14 replicon inhibition and selectivity against BVDV and cytotoxicity.

15 ul prevention and treatment strategy against BVDV infection.

16 icant potential as a subunit vaccine against BVDV infection.

17 ent study, the relationship between HO-1 and BVDV was investigated.

18 of de novo-initiated products by the HCV and BVDV RdRps.

19 ells demonstrated that a decrease in HO-1 as BVDV replication increased.

20 nstrate that mutations in NS4B can attenuate BVDV cytopathogenicity despite NS3 production.

21 opment of a contemporary CD8(+) T cell-based BVDV vaccine capable of addressing BVDV heterogeneity mo

22 although the lack of differentiation between BVDV and HoBi-like viruses would make these tests of lim

23 A bicistronic BVDV (cp strain NADL) was created that expressed puromyc

24 pro region near the N terminus (L8P) in both BVDV biotypes did not antagonize IFN-alpha/beta producti

25 (AZA) and mycophenolate acid (MPA), on both BVDV replication by plaque assay and host-cell replicati

26 ty of the chimeric virus, an Npro-null BVDV (BVDV-Npro in which the entire Npro coding region was del

27 us (HCV) NS3 protease inhibitors, a chimeric BVDV in which the coding region of Npro was replaced by

28 etics between the wild-type and the chimeric BVDVs.

29 The commercial BVDV RT-qPCRs and IHC detected 100% of the ear notch sam

30 Using a set of engineered cp BVDVs expressing mutant Npro and appropriate controls, w

31 bovine cells indicated that cytopathic (cp) BVDV induces IFN-alpha/beta very inefficiently.

32 LDL receptor-deficient cells or a cytolytic BVDV system indicated that the LDL receptor may be the m

33 ction of NS3, a characteristic of cytopathic BVDV strains, is believed to be a consequence of an in-f

34 ation by conferring resistance to cytopathic BVDV-induced cell death.

35 Although cytopathic, BVDV-Npro was highly defective in viral replication and

36 lability of commercial vaccines for decades, BVDV prevalence in cattle has remained largely unaffecte

37 achieved similar cytotoxicity, AZA decreased BVDV replication 10 times more than MPA.

38 adly reactive CD8(+) T cells against diverse BVDV strains.

39 major target of neutralizing antibody during BVDV infection.

40 uggests that they play a crucial role during BVDV infection.

41 he possibility of a linkage between enhanced BVDV NADL RNA replication and virus-induced cytopathogen

42 kdown of TRIM56 expression greatly enhanced, BVDV replication in cell culture.

43 For BVDV NADL, the production of NS3, a characteristic of cy

44 For BVDV, this effect has been attributed to the reduction o

45 engineered back into an infectious cDNA for BVDV (NADL strain), point mutations in either the GKT or

46 characterize essential factors required for BVDV replication, a library expressing random fragments

47 mples were subjected to diagnostic tests for BVDV--two reverse transcriptase PCR (RT-PCR) assays, two

48 and that this block occurred downstream from BVDV interaction with the cellular receptor CD46 and vir

49 purified bovine CD8(+) T cells isolated from BVDV-1- and -2-immunized cattle.

50 y conserved among more than 200 strains from BVDV-1 and -2 genotypes.

51 Finally, using a full-length functional BVDV cDNA clone, we demonstrate that a catalytically act

52 Furthermore, BVDV RdRp was found to utilize a circular single-strande

53 of a single codon in the full-length genomic BVDV cDNA clone, encoding glutamic acid at position 1600

54 protected from superinfection by homologous BVDV but not with heterologous vesicular stomatitis viru

55 However, the function of HO-1 in BVDV infection is unclear.

56 In vitro analysis of HO-1 expression in BVDV-infected MDBK cells demonstrated that a decrease in

57 In contrast, HO-1 siRNA knockdown in BVDV-infected cells increased BVDV replication.

58 -NP) and a commercial adjuvanted inactivated BVDV vaccine (IAV), all inoculated subcutaneously and bo

59 A knockdown in BVDV-infected cells increased BVDV replication.

60 structural protein E2 from primary infecting BVDV abolished this exclusion.

61 Subsequently, we showed that infectious BVDV was produced by cells transfected with uncapped RNA

62 Since compound-1453 did not inhibit BVDV polymerase activity in vitro (50% inhibitory concen

63 re- and postinfection, effectively inhibited BVDV replication.

64 I-binding epitopes were identified from key BVDV Ags that can elicit broadly reactive CD8(+) T cells

65 r initial attempt to produce the full-length BVDV NS5B with a C-terminal hexahistidine tag in Escheri

66 ictions of the region surrounding the mapped BVDV zinc-binding region, indicates that the BVDV zinc-b

67 missive to both cytopathic and noncytopathic BVDV infection compared to parental MDBK cells, although

68 (IFN-alpha/beta), whereas noncytopathogenic BVDV (ncpBVDV) isolates have been shown not to induce IF

69 In addition, from nonstructural BVDV Ags N(pro), NS2-3, NS4A-B, and NS5A-B, 20 CD8(+) T

70 models in IBR (154) and BRSV (195), but not BVDV (74), were related to type I interferon production

71 The C-terminal domain of NS3 (BVDV amino acids 1854 to 2362) of these mutants and wild

72 tability of the chimeric virus, an Npro-null BVDV (BVDV-Npro in which the entire Npro coding region w

73 ein derived from an infectious cDNA clone of BVDV (NADL strain).

74 Suitability of the molecular clone of BVDV for genomic manipulations was shown by substitution

75 onstructed a stable full-length cDNA copy of BVDV NADL in a low-copy-number plasmid vector.

76 This paper describes the dynamics of BVDV antibody test values (measured as percentage positi

77 tion could be overcome by electroporation of BVDV RNA, indicating a block at one or more steps in vir

78 ed a plasmid containing the entire genome of BVDV cloned as cDNA.

79 The inhibition of BVDV by AZA occurred at lower doses than the cellular cy

80 topathic pestiviruses, including isolates of BVDV-1, BVDV-2, border disease virus, and classical swin

81 Phosphorylation of BVDV NS5A and YF NS5 was observed in infected cells, tra

82 In this study, the presence of BVDV-specific CD8(+) T cells that are highly cross-react

83 e amino-terminal cysteine protease N(pro) of BVDV appears to be, at least partly, responsible for sup

84 Similarities in the properties of BVDV NS5A, YF NS5, and HCV NS5A phosphorylation in vitro

85 n was linked in frame to the core protein of BVDV through an HCV NS5A-NS5B junction site and mimicked

86 r the expression and partial purification of BVDV NS5A was developed, and the partially purified prot

87 es were identified from different regions of BVDV polyprotein.

88 oteolytic function of Npro in the release of BVDV core for capsid assembly.

89 ed on longitudinal changes in the results of BVDV antibody tests could offer a novel, complementary a

90 e is limited knowledge regarding the role of BVDV-specific CD8(+) T cells in immune protection, and i

91 We are using a cytopathic strain of BVDV (cpBVDV) that causes cellular apoptosis as a model

92 National Animal Disease Laboratory strain of BVDV.

93 The structure of BVDV polymerase complexed with GTP, which is required fo

94 The structure of BVDV polymerase, determined to 2.9-A resolution, contain

95 etion of 24 amino acids at the C terminus of BVDV NS5B.

96 we isolated drug-resistant (DR) variants of BVDV-1 in cell culture.

97 hibitor molecules specific for either HCV or BVDV can be easily distinguished by using the parallel r

98 polymerase assay using homopolymeric RNA or BVDV minigenomic RNA templates.

99 The parallel BVDV and HCV replicon systems provide robust counterscre

100 bovine viral diarrhea virus RNA polymerase (BVDV RdRp) and RdRps from related positive-strand RNA vi

101 versely correlated with the level of primary BVDV RNA replication.

102 We have purified BVDV core protein and characterized it biochemically.

103 utative binding sites of previously reported BVDV inhibitors are also discussed.

104 Here we show that a subgenomic (sg) BVDV RNA in which the NS3 ORF is preceded only by the 5'

105 ress the E2 protein from type 2 (890 strain) BVDV in a bovine herpesvirus 1 (BHV1) vector, we observe

106 ere identified from the following structural BVDV Ags: E(rns), E1, and E2 glycoproteins.

107 A subgenomic BVDV reporter replicon (rNS3-5B) was used to analyze the

108 Superinfecting BVDV failed to deliver a translatable genome into acutel

109 ating a self-processing polyprotein [GFP-T2A-BVDV-E2(trunk)-V5], producing discrete [GFP-T2A] and [E2

110 We found that BVDV core protein was able to functionally replace the n

111 The BVDV replicon showed similar sensitivity as the HCV repl

112 The BVDV RT-qPCR, ACE, and IHC yielded higher levels of dete

113 In comparison, the BVDV RT-PCR test had a higher rate of false negatives in

114 ion marker and reporter (Luc-Ubi-Neo) in the BVDV replicon was fused with the amino-terminal protease

115 a library expressing random fragments of the BVDV genome was screened for sequences that act as trans

116 cribe the expression and purification of the BVDV NS5B protein derived from an infectious cDNA clone

117 While ACE based on the BVDV glycoprotein E(rns) detected infection in at least

118 the unprocessed fusion protein rendered the BVDV core protein defective in capsid assembly.

119 BVDV zinc-binding region, indicates that the BVDV zinc-binding motif fits the general template Cx(22)

120 ein processing, and cytopathogenicity to the BVDV NADL parent.

121 ther Mn(2+) was present or absent, while the BVDV RdRp efficiently used GDP and GMP for initiation of

122 l transferase activity was observed with the BVDV NS5B preparation.

123 This BVDV replicon allows us to compare RNA replication of th

124 domain was responsible for the inhibition to BVDV entry and that this block occurred downstream from

125 oculated subcutaneously and boosted prior to BVDV-1 challenge.

126 epatitis C virus, a virus closely related to BVDV.

127 L receptor on cells known to be resistant to BVDV infection.

128 itic cells (DCs) produced IFN in response to BVDV in vitro.

129 Like the wild-type BVDV (NADL), the chimeric virus was cytopathic and forme

130 gesting interference with a yet-unidentified BVDV entry factor.

131 We evaluated this model using BVDV E2 and NS3 proteins formulated in poly-(D, L-lactic

132 Given the changing dynamics of BVD virus (BVDV) antibody responses in cattle, classifying herds ba

133 (PI) with bovine viral diarrhea (BVD) virus (BVDV) constitute the mechanism by which BVDV persists in

134 Bovine viral diarrhea virus (BVDV) (genus Pestivirus) was reported to trigger interfe

135 the pestivirus bovine viral diarrhea virus (BVDV) (NADL strain) is required for processing at nonstr

136 e motifs of the bovine viral diarrhea virus (BVDV) (NADL strain) NS3 protein designed to abolish eith

137 uses, including bovine viral diarrhea virus (BVDV) and the emerging HoBi-like viruses.

138 espectively, of bovine viral diarrhea virus (BVDV) and yellow fever virus (YF), members of the other

139 s noncytopathic bovine viral diarrhea virus (BVDV) can suppress IFN production in the majority of cel

140 in 5B (NS5B) of bovine viral diarrhea virus (BVDV) contains sequence motifs that are predictive of an

141 gainst selected bovine viral diarrhea virus (BVDV) genes has gained widespread interest.

142 encoded by the bovine viral diarrhea virus (BVDV) genome is a cysteine protease (Npro) responsible f

143 us vaccines for bovine viral diarrhea virus (BVDV) have their limitations.

144 replication of bovine viral diarrhea virus (BVDV) in cell culture at a 50% inhibitory concentration

145 ic replicon for bovine viral diarrhea virus (BVDV) in Huh-7 cells, similar to that established for he

146 he detection of bovine viral diarrhea virus (BVDV) in pooled bovine serum samples.

147 Bovine viral diarrhea virus (BVDV) is a positive-strand RNA virus and a member of the

148 Bovine viral diarrhea virus (BVDV) is a positive-stranded RNA virus of the Flavivirid

149 the pestivirus bovine viral diarrhea virus (BVDV) is a zinc-binding protein.

150 Bovine viral diarrhea virus (BVDV) is in the Flaviviridae family and is closely relat

151 Bovine viral diarrhea virus (BVDV) is the most insidious and devastating viral pathog

152 y expression of bovine viral diarrhea virus (BVDV) N(PRO) protein targeting IRF3 as part of the cGAS/

153 Recombinant bovine viral diarrhea virus (BVDV) nonstructural protein 5B (NS5B) produced in insect

154 The bovine viral diarrhea virus (BVDV) RNA-dependent RNA polymerase can initiate RNA repl

155 n initiation of bovine viral diarrhea virus (BVDV) RNA.

156 a noncytopathic bovine viral diarrhea virus (BVDV) strain, Kyle.

157 the function of bovine viral diarrhea virus (BVDV) uncleaved NS2-3.

158 ses elicited by bovine viral diarrhea virus (BVDV) vaccines have primarily focused on the characteriz

159 novel mutant of bovine viral diarrhea virus (BVDV) was found with a virion assembly phenotype attribu

160 ase (N(pro)) of bovine viral diarrhea virus (BVDV), a pestiviral interferon antagonist which degrades

161 on exclusion of bovine viral diarrhea virus (BVDV), a positive-sense RNA pestivirus.

162 C virus (HCV), bovine viral diarrhea virus (BVDV), and GB virus-B all can initiate RNA synthesis by

163 virus-B (GBV), bovine viral diarrhea virus (BVDV), and hepatitis C virus (HCV), with emphasis on the

164 uses, including bovine viral diarrhea virus (BVDV), are important animal pathogens and close relative

165 virus (HCV) and bovine viral diarrhea virus (BVDV), lipid droplets, and secreted lipoproteins.

166 Bovine viral diarrhea virus (BVDV), strain NADL, was originally isolated from an anim

167 Isolates of bovine viral diarrhea virus (BVDV), the prototype pestivirus, are divided into cytopa

168 the pestivirus bovine viral diarrhea virus (BVDV).

169 ruses including Bovine viral diarrhea virus (BVDV).

170 amplified from bovine viral diarrhea virus (BVDV).

171 e E2 protein of bovine viral diarrhea virus (BVDV).

172 ic inhibitor of bovine viral diarrhea virus (BVDV).

173 s G virus, and bovine viral diarrheal virus (BVDV) was shown to be mediated by low density lipoprotei

174 is is true for bovine viral diarrhoea virus (BVDV), the causative agent of BVD that is a worldwide th

175 rus (BVDV) constitute the mechanism by which BVDV persists in cattle herds.

176 available bovine sera are contaminated with BVDV and, although there is no evidence that the virus i

177 7 bovine sera tested were contaminated with BVDV.

178 Cells acutely infected with BVDV were protected from superinfection by homologous BV

179 esence of animals persistently infected with BVDV.

180 lasmacytoid DCs harvested postinfection with BVDV or recombinant bovine IFN-alpha or human IL-28B sig

181 tious clone of drug-sensitive wild-type (WT) BVDV-1, replication of the resulting virus was resistant